News

Video

ASCRS 2024: Neurotech Pharmaceuticals CEO gives update on future plans for NT-501

Rich Small, CEO of Neurotech Pharmaceuticals, provides an update on the months ahead for NT-501 encapsulated cell therapy

Rich Small, CEO of Neurotech Pharmaceuticals, provides an update on the months ahead for NT-501 encapsulated cell therapy

Video Transcript:

Rich Small:

Hi, I'm Rich Small, CEO of Neurotech Pharmaceuticals. We already have a very novel technology we call encapsulated cell therapy [ECT], which consists of genetically-modified cells that are designed to release therapeutic factors over a sustained period of time into the back of the eye. Our most advanced ECT product is called NT-501, which releases a neurotrophic factor, CNTF. And we've been studying CNTF for an orphan disease called macular telangiectasia, or MacTel. We have completed our phase III studies with very positive results, showing slowing down progression of disease over a two-year period of time. Also at Neurotech, we've been putting our final touches on preparing to submit to the FDA our biological license application. We are hopefully to submit it shortly. As well, we are creating and growing our infrastructure. So we recently have built out our commercial team. We've added to our clinical and medical affairs team. And we also are planning to manufacture our product for commercialization, hopefully, once we get through approval. So all in all, a lot of exciting things going on in Neurotech We're very excited and we will be keeping you updated as we make progress over the coming months. Thank you very much

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.